Human metapneumovirus is a respiratory Iract infectious virus,its infection is mainly in young children.elderly and immunocompromised patients.It is responsible for about 5%-1O%of hospitalized children suffering from acute respiratory tract infections.This paper reviews human metapneumovirus about its virology,epidemiology and clinical manifestations and so on. Key words: Respiratory tract infection; Human metapneumovirus; Children

A new human pneumovirus, provisionally designated human metapneumovirus, was discovered by Dutch researchers. We examined 142 serum samples from the general population aged from 1 month to 35 years in Japan for human metapneumovirus antibody by indirect immunofluorescence assays using human metapneumovirus-infected monkey kidney cells. The overall prevalence of human metapneumovirus infection was 72.5%. The seropositive rate was lowest in the age group of 6 months to 1 year and gradually increased with age. All of the children had been exposed to human metapneumovirus by the age of 10 years. The results show that human metapneumovirus is circulating in the Japanese population and is a ubiquitous virus acquired early in life.

Human metapneumovirus (HMPV, MPV) is a member of the Paramyxoviridae family that causes upper and lower respiratory tract disease in humans. The MPV genome is a single-stranded, negative-sense ribonucleic acid. Analysis of sequences and gene identification placed the novel virus in the genus Metapneumovirus with sequence homology most similar to APV-type C (APV-C). Thus, the virus was named human metapneumovirus, and it is the only identified human pathogen in this genus. Sequence data for MPV revealed eight genes, which code for nine proteins. MPV genes have high sequence identity with APV-C and some similarities to other Pneumoviruses in the open reading frame regions. The MPV F protein, a type I glycoprotein, also contains two regions of glycine-poor heptad repeats. The fact that MPV was identified only recently can be partially attributed to poor virus growth in common continuous cell lines, including tertiary monkey kidney and Vero cells.

Human metapneumovirus is known to be similar to respiratory syncytial virus. Because of an incomplete protective immune response to new genotypes, re-infection occurs frequently, especially in the elderly. However, the clinical manifestations of human metapneumovirus need to be further characterized in adults. A 73-year-old woman presented to the emergency room with acute dyspnea, chest discomfort and influenza-like illness. The patient was diagnosed with human metapneumovirus infection, complicated by pneumonia and myopericarditis. With supportive care including oxygen supplementation, the patient recovered completely without any serious sequelae. Human metapneumovirus infection may contribute to the development of cardiovascular manifestations, particularly in the elderly population.

We retrospectively studied 420 pharyngeal swab specimens collected from Peruvian and Argentinean patients with influenzalike illness in 2002 and 2003 for evidence of human metapneumovirus (HMPV). Twelve specimens (2.3%) were positive by multiple assays. Six specimens yielded HMPV isolates. Four of the 6 isolates were of the uncommon B1 genotype.

Human metapneumovirus (HMPV) is a pre-existing negative sense RNA virus of the family Paramyxoviridae, manifesting lower respiratory tract infections in children and adults above the age of 65 years. It replicates in a gradient manner similar to other paramyxovirus and spreads through droplets (released during cough or sneeze) or direct contact with contaminated surfaces. This virus and its history of infections show a characteristic curve with time increasing periodically during the winter, like other respiratory infections such as influenza.

Human metapneumovirus is a recently discovered pathogen that causes upper and lower respiratory tract disease in children. This study describes the course of illness in hospitalized children with this infection. During a 6-month period, 11 children were diagnosed with human metapneumovirus infection by reverse transcription-polymerase chain reaction. Oxygen supplementation was required for 82% of patients. Severe disease developed in 45%, and mechanical ventilation was required. An apparent life-threatening event was the indication for hospitalization of 27% of patients infected with human metapneumovirus. Children with underlying asthma or neuromuscular disease had a prolonged hospitalization.

The article analyzes the epidemiological characteristics of Human metapneumovirus, its role in the structure of respiratory diseases, possible complications, and socio-economic consequences for society. Special attention is paid to the prospects for integrating preventive measures against Human metapneumovirus into national immunization programs, as well as the challenges facing medicine and pharmacy in the context of developing vaccines and therapeutic approaches to treating the infection. The article is devoted to the analysis of modern challenges associated with the spread of Human metapneumovirus, its impact on the healthcare sector, medicine, and pharmacy. Human metapneumovirus is a significant respiratory pathogen that causes upper and lower respiratory tract infections, especially among children, the elderly, and people with weakened immune systems. The article examines the epidemiological characteristics of Human metapneumovirus, its seasonality, and the problems of diagnosing and preventing the infection. Special attention is paid to the role of Human metapneumovirus in the structure of respiratory diseases and the need to integrate preventive measures against this virus into national vaccination programs. The article analyzes the current changes to the national vaccination schedule in Ukraine, proposed by the Ministry of Health, as well as their potential impact on reducing the incidence of respiratory infections. The current challenges for pharmaceuticals related to the development of vaccines and therapeutics against Human metapneumovirus, as well as the socio-economic aspects of combating the infection, are discussed. The article emphasizes the importance of an interdisciplinary approach to solving the problem of Human metapneumovirus, which includes cooperation between epidemiologists, physicians, pharmacists, and representatives of state bodies.

In a pediatric surveillance network, 287 (5.1%) of 5,580 specimens from patients with acute respiratory infections tested positive for human metapneumovirus (HMPV). Phylogenetic analysis of N- and F-gene sequences of identified HMPV showed that 30% belonged to a novel phylogenetic cluster.

Investigators at Cincinnati Children's Hospital, OH, report 2 toddlers, ages 15 and 18 months, with human metapneumovirus (hMPV) infection who presented in status epilepticus and later developed respiratory failure.